John Libbey Eurotext

Bulletin du Cancer

MENU

Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy Volume 96, issue 10, octobre 2009

Figures

See all figures

Authors
Département de radiothérapie, centre René-Gauducheau, boulevard Jacques-Monod, 44805 Nantes Saint-Herblain, France, Département de radiothérapie, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France, Département d’oncologie médicale, centre hospitalier intercommunal, 1208, avenue du Colonel-Picot, 83056 Toulon, France, Département d’oncologie médicale, centre Léon-Bérard, 28, rue Laennec, 69373 Lyon, France, Département d’oncologie médicale, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France, Département d’ORL et de chirurgie cervicofaciale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France, Service d’ORL et de chirurgie cervicofaciale, hôpital Tenon, 20, rue de Chine, 75020 Paris, France, Service d’ORL, centre hospitalier régional, 14, avenue de l’Hôpital, 45100 Orléans, France, Service d’ORL et de chirurgie maxillofaciale, centre hospitalier universitaire Caremeau, place du Professeur-Robert-Debré, 30029 Nîmes, France, Laboratoire d’oncopharmacologie, centre Antoine-Lacassagne, 33, rue de Valombrose, 06189 Nice, France, Département d’oncologie médicale, centre René-Gauducheau, boulevard Jacques-Monod, 44805 Nantes Saint-Herblain, France, Département de cancérologie cervicofaciale, Centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59020 Lille, France
  • Key words: head and neck cancers, docetaxel, predictive factors, indications, treatment modalities
  • DOI : 10.1684/bdc.2009.0951
  • Page(s) : 1013-28
  • Published in: 2009

PurposeThe purpose of the present article was to evaluate indications, regimens, treatment modalities, and predictive factors of response to treatment in locally advanced squamous cell carcinoma of the head and neck (SCCHN).MethodsAn expert panel including otolaryngology and head and neck surgery specialists, oncologists, radiotherapists and biologists analyzed the literature providing a synthesis and giving some recommendations.SynthesisFindings from the main randomized phase III trials highlight that the TPF regimen (docetaxel, cisplatin, fluorouracil) represent a preferential option when induction chemotherapy is indicated in either operable or non-operable patients. Given the potential fragility of patients presenting with SCCHN, treatment modalities in routine use require applying preventive measures and tailored follow-up according to each patient’s profile. As regards predictive factors of response to TPF regimen, no factor is currently validated, but ongoing trials should provide better knowledge.ConclusionProgresses in induction chemotherapy have allowed improving the prognosis of patients with locally advanced SCCHN. The TPF regimen represents a major improvement in this indication, and ongoing strategic clinical trials should refine its indications.